{"id":"trastuzumab-hyaluronidase-oysk","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Abdominal pain"},{"rate":"5-10%","effect":"Injection site reaction"}]},"_chembl":{"chemblId":"CHEMBL1201636","moleculeType":"Enzyme"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Trastuzumab is a monoclonal antibody that binds to the HER2/neu receptor on cancer cells, which can help slow or stop the growth of these cells. Hyaluronidase is an enzyme that breaks down hyaluronic acid, a substance that can make it difficult for the drug to spread evenly throughout the body. By breaking down this substance, hyaluronidase helps the drug reach the cancer cells more effectively.","oneSentence":"Trastuzumab targets the HER2/neu receptor, while hyaluronidase is an enzyme that helps the drug spread more evenly throughout the body.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:39:49.108Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adjuvant treatment of HER2-positive breast cancer"},{"name":"Treatment of HER2-positive metastatic breast cancer"}]},"trialDetails":[{"nctId":"NCT05256225","phase":"PHASE3","title":"Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-16","conditions":"Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma","enrollment":360},{"nctId":"NCT06100874","phase":"PHASE2","title":"A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Adrienne G. Waks","startDate":"2023-11-20","conditions":"Her 2 Positive Breast Cancer, Breast Cancer Female, Breast Cancer Metastatic","enrollment":28},{"nctId":"NCT06439693","phase":"PHASE2","title":"The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-08-08","conditions":"Breast Cancer Female, Breast Cancer, Breast Cancer Metastatic","enrollment":72}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Herceptin Hylecta","Trastuzumab and Hyaluronidase","Trastuzumab and Hyaluronidase-oysk","Trastuzumab and Recombinant Human Hyaluronidase PH20","Trastuzumab and rHuPH20"],"phase":"phase_3","status":"active","brandName":"Trastuzumab/Hyaluronidase-oysk","genericName":"Trastuzumab/Hyaluronidase-oysk","companyName":"National Cancer Institute (NCI)","companyId":"national-cancer-institute-nci","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Trastuzumab targets the HER2/neu receptor, while hyaluronidase is an enzyme that helps the drug spread more evenly throughout the body. Used for Adjuvant treatment of HER2-positive breast cancer, Treatment of HER2-positive metastatic breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}